Drug Discovery · Boston, MA · Founded 2018 · Privately Held (backing)
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. Imbria Pharmaceuticals is based in Boston, MA and was founded in 2018. It was valued at $132 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $152 million across 2 recorded rounds; the latest was a $66.7 million Series B in Dec 2025.
PMV mark · valuation
$131.7M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$151.9M
Last round
Later Stage VC (Series B)
Dec 2025
Cap table — not yet on record
Imbria Pharmaceuticals's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Imbria Pharmaceuticals with a free account
·Watch Imbria Pharmaceuticals: the Monday email on marks, rounds and moves
Where does Imbria Pharmaceuticals's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Imbria Pharmaceuticals's 2 recorded funding rounds.
